In vivo optoacoustic imaging of endothelin receptor expression and treatment response in the hypoxic tumor microenvironment
- PMID: 40802092
- DOI: 10.1007/s00259-025-07494-7
In vivo optoacoustic imaging of endothelin receptor expression and treatment response in the hypoxic tumor microenvironment
Abstract
Purpose: A hypoxic tumor microenvironment promotes cancer progression, with endothelin-A receptor (ETAR) signaling playing a key role in tumor neoangiogenesis and macrophage infiltration. We hypothesize that multispectral optoacoustic tomography (MSOT) using an ETAR-specific probe could provide improved insights into the hypoxic characteristics of the tumor microenvironment (TME), either alone or in combination with endogenous markers, and that alterations in ETAR expression may correlate with increased tumor oxygenation serving as an early indicator of response to anti-angiogenic or immune-modulating therapy.
Methods: A fluorescent ETAR probe was applied for in vivo MSOT evaluation of ETAR expression in hypoxic murine breast cancer. Optoacoustic signal intensity (SI) of deoxygenated and oxygenated hemoglobin served as additive intrinsic readouts. Furthermore, therapeutic interventions utilizing Bevacizumab, Clodronate and Sorafenib were evaluated with regard to effects on ETAR expression and hemoglobin oxygen saturation. Imaging results were validated ex vivo via immunohistochemistry.
Results: Exposure of 4T1 murine breast cancer cells to hypoxic conditions led to upregulation of ETAR in vitro. In vivo, tumor growth correlated with increased ETAR probe signal intensity in 4T1 tumors. All therapeutic interventions significantly reduced ETAR SI following treatment. Anti-angiogenic therapies also increased tumor oxygen saturation, indicating therapy-induced re-oxygenation.
Conclusion: ETAR expression in hypoxic tumor regions can be visualized non-invasively by MSOT using an exogenously administered targeted probe. Combining ETAR-targeted imaging with intrinsic hemoglobin readouts enables assessment of reoxygenation and immune cell modulation in response to therapy. Thus, ETAR has potential as an in vivo imaging biomarker for early therapy response in experimental breast cancer studies.
Keywords: Endothelin system; In vivo imaging; Optoacoustic tomography; Tumor hypoxia; Tumor microenvironment.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Disclosure: The authors have no relevant financial or non-financial interests to disclose.
Similar articles
-
Systemic treatments for metastatic cutaneous melanoma.Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2. Cochrane Database Syst Rev. 2018. PMID: 29405038 Free PMC article.
-
Tumor therapy by targeting extracellular hydroxyapatite using novel drugs: A paradigm shift.Cancer Med. 2024 Feb;13(3):e6812. doi: 10.1002/cam4.6812. Epub 2024 Jan 18. Cancer Med. 2024. PMID: 38239047 Free PMC article.
-
Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1/PD-L1 therapy.Front Immunol. 2025 Jul 24;16:1557461. doi: 10.3389/fimmu.2025.1557461. eCollection 2025. Front Immunol. 2025. PMID: 40777041 Free PMC article.
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
CD24a knockout results in an enhanced macrophage- and CD8⁺ T cell-mediated anti-tumor immune responses in tumor microenvironment in a murine triple-negative breast cancer model.J Biomed Sci. 2025 Aug 9;32(1):73. doi: 10.1186/s12929-025-01165-3. J Biomed Sci. 2025. PMID: 40783744 Free PMC article.
References
-
- Harris AL. Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38–47. https://doi.org/10.1038/nrc704 . - DOI - PubMed
-
- Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721–32. https://doi.org/10.1038/nrc1187 . - DOI - PubMed
-
- Wicks EE, Semenza GL. Hypoxia-inducible factors: cancer progression and clinical translation. J Clin Invest. 2022. https://doi.org/10.1172/JCI159839 . - DOI - PubMed - PMC
-
- He Z, Zhang S. Tumor-associated macrophages and their functional transformation in the hypoxic tumor microenvironment. Front Immunol. 2021;12:741305. https://doi.org/10.3389/fimmu.2021.741305 . - DOI - PubMed - PMC
-
- Jeong H, Kim S, Hong BJ, Lee CJ, Kim YE, Bok S, et al. Tumor-Associated macrophages enhance tumor hypoxia and aerobic Glycolysis. Cancer Res. 2019;79:795–806. https://doi.org/10.1158/0008-5472.CAN-18-2545 . - DOI - PubMed
LinkOut - more resources
Full Text Sources